These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11761251)

  • 1. Developing an approach to evaluate the use of neoplastic cells as vaccine substrates.
    Lewis AM
    Dev Biol (Basel); 2001; 106():37-42; discussion 42-3. PubMed ID: 11761251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
    Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
    Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture.
    Lewis AM; Krause P; Peden K
    Dev Biol (Basel); 2001; 106():513-35. PubMed ID: 11761266
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons from preventive infectious disease vaccines.
    Chandler DK; Midthun K; Goldenthal KL
    Dev Biol (Basel); 2004; 116():61-6; discussion 69-76. PubMed ID: 15603184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues of biological assays for viral vaccines.
    Lee CK
    Dev Biol Stand; 1996; 88():41-7. PubMed ID: 9119161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues associated with residual cell-substrate DNA in viral vaccines.
    Sheng-Fowler L; Lewis AM; Peden K
    Biologicals; 2009 Jun; 37(3):190-5. PubMed ID: 19285882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory issues relating to the use of recombinant vectors in production of human vaccines.
    Marcus-Sekura CJ
    Dev Biol Stand; 1994; 82():107-12. PubMed ID: 7958464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potency assays for therapeutic live whole cell cancer vaccines.
    Petricciani J; Egan W; Vicari G; Furesz J; Schild G
    Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction.
    Khan AS; Ma W; Ma Y; Kumar A; Williams DK; Muller J; Ma H; Galvin TA
    Biologicals; 2009 Jun; 37(3):196-201. PubMed ID: 19299169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of adventitious viruses in biologicals--a rare occurrence.
    Nims RW
    Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.
    Cutrone R; Lednicky J; Dunn G; Rizzo P; Bocchetta M; Chumakov K; Minor P; Carbone M
    Cancer Res; 2005 Nov; 65(22):10273-9. PubMed ID: 16288015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line.
    Ledwith BJ; Lanning CL; Gumprecht LA; Anderson CA; Coleman JB; Gatto NT; Balasubramanian G; Farris GM; Kemp RK; Harper LB; Barnum AB; Pacchione SJ; Mauer KL; Troilo PF; Brown ER; Wolf JJ; Lebronl JA; Lewis JA; Nichols WW
    Dev Biol (Basel); 2006; 123():251-63; discussion 265-6. PubMed ID: 16566451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conceptual and experimental approaches to address product safety issues raised by novel cell substrates.
    Krause PR
    Dev Biol (Basel); 2001; 106():45-8; discussion 49-50. PubMed ID: 11761261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of vaccines: strengthening the science base.
    Milstien JB
    J Public Health Policy; 2004; 25(2):173-89; discussion 190-6. PubMed ID: 15255384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrovirus screening of vaccine cell substrates.
    Khan AS
    Dev Biol Stand; 1996; 88():157-62. PubMed ID: 9119131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell substrates: where do we stand after 50 years of discussion?
    Petricciani J
    Dev Biol (Basel); 2006; 123():11-21; discussion 55-73. PubMed ID: 16566432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.